Skip to main content
Pharmaco Vigilance
Search form
Search
Home
Perspectives
Case Reports
Focus on
Columns
News
Links
About us
Contacts
News
February 2022
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021
January 2022
A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination
January 2022
Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination
January 2022
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
December 2021
New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine
December 2021
A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination
December 2021
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
November 2021
Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
November 2021
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
November 2021
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
80.211.154.110
